Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Slides:

Advertisements

Similar presentations

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.

Advertisements

1 National and Kapodistrian University of Athens, Athens, Greece; 2 Mayo Clinic, Scottsdale, AZ; 3 Division of Hematology, Mayo Clinic, Rochester, MN;

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Future Strategies for Myeloma

Presented By Michele Cavo at 2016 ASCO Annual Meeting

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front- line therapy with novel agents combinations Aurelio Lopez, Maria-Victoria.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

How I treat multiple myeloma in younger patients

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis.

Absence of biologically important Kaposi sarcoma–associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.

The role of complete response in multiple myeloma

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping by David C. Johnson, Sophie Corthals,

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma by Massimo.

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome by Fiorina.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone by Patrizia Tosi, Elena.

Blocking VWF platelet binding to treat TTP

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional.

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:

by Kaiwen Chen, Matthew P. Cheng, Sarah P

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study.

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

by Wendy Lim, Sara K. Vesely, and James N. George

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Treatment versus Transplant for Challenging Hematologic Disorders

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Treatment options for relapsed and refractory multiple myeloma

by Robert A. Kyle, and S. Vincent Rajkumar

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary.

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term.

Initial treatment of CLL: integrating biology and functional status

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL.

Cold agglutinin disease

Presentation transcript:

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo, Sara Bringhen, Heinz Ludwig, Meletios A. Dimopoulos, Joan Bladé, Maria V. Mateos, Laura Rosiñol, Mario Boccadoro, Michele Cavo, Henk Lokhorst, Sonja Zweegman, Evangelos Terpos, Faith Davies, Christoph Driessen, Peter Gimsing, Martin Gramatzki, Roman Hàjek, Hans E. Johnsen, Fernando Leal Da Costa, Orhan Sezer, Andrew Spencer, Meral Beksac, Gareth Morgan, Hermann Einsele, Jesus F. San Miguel, and Pieter Sonneveld Blood Volume 118(17): October 27, 2011 ©2011 by American Society of Hematology

Five-year relative survival rates according to the year of diagnosis and the patients' age at diagnosis. Antonio Palumbo et al. Blood 2011;118: ©2011 by American Society of Hematology

The interrelation between the 3 components of vulnerability (comorbidity, frailty, and disability) and the main health care implications associated with each factor. Antonio Palumbo et al. Blood 2011;118: ©2011 by American Society of Hematology

Treatment algorithm for elderly frail patients (adapted from Palumbo and Anderson46). Antonio Palumbo et al. Blood 2011;118: ©2011 by American Society of Hematology